Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Nov 4;2(1):14-5.
doi: 10.1016/j.gynor.2011.10.007. eCollection 2011.

Malignant melanoma arising in mature cystic teratoma of the ovary

Heidi E Godoy  1 , Joshua P Kesterson  1 , John M Kasznica  2 , Shashikant Lele  1
Affiliations

Malignant melanoma arising in mature cystic teratoma of the ovary

Heidi E Godoy et al. Gynecol Oncol Case Rep. .

Abstract

► Teratomas are composed of elements of all three germ layers, all potentially capable of undergoing malignant transformation. ► A case of malignant melanoma arising in a mature teratoma is presented.

Keywords: Malignant melanoma; Mature teratoma.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Malignant melanoma component of mature teratoma. The tumor cells show a sheet-like pattern, nuclear pleomorphism, melanin pigment and mitotic figures. (Hematoxylin-Eosin, 400 × magnification).
See this image and copyright information in PMC

References

    1. Boughton R.S., Hughmanick S., Marin-Padilla M. Malignant melanoma arising in an ovarian cystic teratoma in pregnancy. J. Am. Acad. Dermatol. 1987;17:871–875. - PubMed
    1. Dasgupta T., Brasfield R. Metastatic Melanoma. A Clinicopathological Study. Cancer. 1964;17:1323–1339. - PubMed
    1. Hodi F.S., Friedlander P., Corless C.L., Heinrich M.C., Mac Rae S., Kruse A., Jagannathan J., Van den Abbeele A.D., Velazquez E.F., Demetri G.D., Fisher D.E. Major response to imatinib mesylate in KIT-mutated melanoma. J. Clin. Oncol. 2008;26:2046–2051. - PubMed
    1. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., Akerley W., van den Eertwegh A.J., Lutzky J., Lorigan P., Vaubel J.M., Linette G.P., Hogg D., Ottensmeier C.H., Lebbe C., Peschel C., Quirt I., Clark J.I., Wolchok J.D., Weber J.S., Tian J., Yellin M.J., Nichol G.M., Hoos A., Urba W.J. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010;363:711–723. - PMC - PubMed
    1. Neyns B., Tosoni A., Hwu W.J., Reardon D.A. Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects. Cancer. 2010;116:2868–2877. - PubMed

LinkOut - more resources